Piet Borst
YOU?
Author Swipe
View article: Abnormal Left Atrial Strain by CMR Is Associated With Left Heart Disease in Patients With Pulmonary Hypertension
Abnormal Left Atrial Strain by CMR Is Associated With Left Heart Disease in Patients With Pulmonary Hypertension Open
BACKGROUND: Pulmonary hypertension (PH) is classified as precapillary, isolated postcapillary pulmonary hypertension (IpcPH), combined postcapillary and precapillary (CpcPH), or exercise PH. IpcPH associated with left heart disease can lea…
View article: Supplementary Figure Legends 1-10 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
Supplementary Figure Legends 1-10 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors Open
PDF file - 86K
View article: Data from Lack of ABCG2 Shortens Latency of BRCA1-Deficient Mammary Tumors and This Is Not Affected by Genistein or Resveratrol
Data from Lack of ABCG2 Shortens Latency of BRCA1-Deficient Mammary Tumors and This Is Not Affected by Genistein or Resveratrol Open
In addition to their role in drug resistance, the ATP-binding cassette (ABC) transporters ABCG2 and ABCB1 have been suggested to protect cells from a broad range of substances that may foster tumorigenesis. Phytoestrogens or their metaboli…
View article: Supplementary Figure 1 from Lack of ABCG2 Shortens Latency of BRCA1-Deficient Mammary Tumors and This Is Not Affected by Genistein or Resveratrol
Supplementary Figure 1 from Lack of ABCG2 Shortens Latency of BRCA1-Deficient Mammary Tumors and This Is Not Affected by Genistein or Resveratrol Open
PDF file - 28K, Influence of ovariectomy on skin tumor incidence of K14cre;Brca1F/F;p53F/F females, fed with three special diets
View article: Supplementary Tables 1-2 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
Supplementary Tables 1-2 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors Open
PDF file - 28K, Information on all antibodies and primers that were used in this study
View article: Supplementary Tables 1-2 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
Supplementary Tables 1-2 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors Open
PDF file - 28K, Information on all antibodies and primers that were used in this study
View article: Supplementary Figures 1-10 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
Supplementary Figures 1-10 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors Open
PDF file - 1.2MB, This file contains additional data on tumor responses to olaparib treatment (Fig. S1 and S2), pH2AX stainings on treated and untreated tumors (Fig. S3), analysis of mutations in 53BP1 (Fig. S4 and S7B), characterization o…
View article: Data from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
Data from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors Open
Inhibition of PARP is a promising therapeutic strategy for homologous recombination–deficient tumors, such as BRCA1-associated cancers. We previously reported that BRCA1-deficient mouse mammary tumors may acquire resistance to the clinical…
View article: Data from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
Data from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors Open
Inhibition of PARP is a promising therapeutic strategy for homologous recombination–deficient tumors, such as BRCA1-associated cancers. We previously reported that BRCA1-deficient mouse mammary tumors may acquire resistance to the clinical…
View article: Supplementary Figure Legends 1-10 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
Supplementary Figure Legends 1-10 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors Open
PDF file - 86K
View article: Supplementary Figure 1 from Lack of ABCG2 Shortens Latency of BRCA1-Deficient Mammary Tumors and This Is Not Affected by Genistein or Resveratrol
Supplementary Figure 1 from Lack of ABCG2 Shortens Latency of BRCA1-Deficient Mammary Tumors and This Is Not Affected by Genistein or Resveratrol Open
PDF file - 28K, Influence of ovariectomy on skin tumor incidence of K14cre;Brca1F/F;p53F/F females, fed with three special diets
View article: Supplementary Figures 1-10 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
Supplementary Figures 1-10 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors Open
PDF file - 1.2MB, This file contains additional data on tumor responses to olaparib treatment (Fig. S1 and S2), pH2AX stainings on treated and untreated tumors (Fig. S3), analysis of mutations in 53BP1 (Fig. S4 and S7B), characterization o…
View article: Data from Lack of ABCG2 Shortens Latency of BRCA1-Deficient Mammary Tumors and This Is Not Affected by Genistein or Resveratrol
Data from Lack of ABCG2 Shortens Latency of BRCA1-Deficient Mammary Tumors and This Is Not Affected by Genistein or Resveratrol Open
In addition to their role in drug resistance, the ATP-binding cassette (ABC) transporters ABCG2 and ABCB1 have been suggested to protect cells from a broad range of substances that may foster tumorigenesis. Phytoestrogens or their metaboli…
View article: Data from Selected Alkylating Agents Can Overcome Drug Tolerance of G<sub>0</sub>-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice
Data from Selected Alkylating Agents Can Overcome Drug Tolerance of G<sub>0</sub>-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice Open
Purpose: We aimed to characterize and target drug-tolerant BRCA1-deficient tumor cells that cause residual disease and subsequent tumor relapse.Experimental Design: We studied responses to various mono- and bifunctional alkylating agents i…
View article: Supplementary Figure Legends from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
Supplementary Figure Legends from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides Open
Supplementary Figure Legends from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
View article: Supplementary Fig. S2 from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
Supplementary Fig. S2 from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides Open
Supplementary Fig. S2 from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
View article: Supplementary Fig. S1 from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
Supplementary Fig. S1 from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides Open
Supplementary Fig. S1 from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
View article: Supplementary Fig. S1 from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
Supplementary Fig. S1 from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides Open
Supplementary Fig. S1 from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
View article: Supplementary Figures S1-S8 from Selected Alkylating Agents Can Overcome Drug Tolerance of G<sub>0</sub>-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice
Supplementary Figures S1-S8 from Selected Alkylating Agents Can Overcome Drug Tolerance of G<sub>0</sub>-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice Open
Figure S1: Treatment response to cisplatin spread over several days. Figure S2: Cisplatin adducts in tumor remants; GFP-marker in the BRCA1-deficient mouse model. Figure S3: EdU incorporation assay. Figure S4: Genomic profile and clonogeni…
View article: Supplementary Figure Legends from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
Supplementary Figure Legends from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides Open
Supplementary Figure Legends from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
View article: Data from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
Data from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides Open
We have studied the potential contribution of ABCG2 (breast cancer resistance protein) to resistance to nucleoside analogues. In cells transfected with DNA constructs resulting in overexpression of human or mouse ABCG2, we found resistance…
View article: Data from Selected Alkylating Agents Can Overcome Drug Tolerance of G<sub>0</sub>-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice
Data from Selected Alkylating Agents Can Overcome Drug Tolerance of G<sub>0</sub>-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice Open
Purpose: We aimed to characterize and target drug-tolerant BRCA1-deficient tumor cells that cause residual disease and subsequent tumor relapse.Experimental Design: We studied responses to various mono- and bifunctional alkylating agents i…
View article: Data from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
Data from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides Open
We have studied the potential contribution of ABCG2 (breast cancer resistance protein) to resistance to nucleoside analogues. In cells transfected with DNA constructs resulting in overexpression of human or mouse ABCG2, we found resistance…
View article: Supplementary Figures S1-S8 from Selected Alkylating Agents Can Overcome Drug Tolerance of G<sub>0</sub>-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice
Supplementary Figures S1-S8 from Selected Alkylating Agents Can Overcome Drug Tolerance of G<sub>0</sub>-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice Open
Figure S1: Treatment response to cisplatin spread over several days. Figure S2: Cisplatin adducts in tumor remants; GFP-marker in the BRCA1-deficient mouse model. Figure S3: EdU incorporation assay. Figure S4: Genomic profile and clonogeni…
View article: Supplementary Fig. S2 from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
Supplementary Fig. S2 from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides Open
Supplementary Fig. S2 from Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
View article: Supplementary Methods from Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors
Supplementary Methods from Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors Open
PDF file - 44K
View article: Supplementary Tables 1-3 from Moderate Increase in <i>Mdr1a/1b</i> Expression Causes <i>In vivo</i> Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer
Supplementary Tables 1-3 from Moderate Increase in <i>Mdr1a/1b</i> Expression Causes <i>In vivo</i> Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer Open
Supplementary Tables 1-3 from Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer
View article: Supplementary Figures 1-7 from Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors
Supplementary Figures 1-7 from Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors Open
PDF file - 751K
View article: Data from Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors
Data from Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors Open
The lack of markers to predict chemotherapy responses in patients poses a major handicap in cancer treatment. We searched for gene expression patterns that correlate with docetaxel or cisplatin response in a mouse model for breast cancer a…
View article: Supplementary Tables 1-6 from Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors
Supplementary Tables 1-6 from Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors Open
PDF file - 514K